14 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 12 Phase 3, 3 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 9, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 1 | Completed 1 |
Follow Complicated Intra-abdominal Infection: new trials by email Literature Review of Complicated Intra-abdominal Infection trials Research Report on Complicated Intra-abdominal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection | Recruiting | Pfizer | 600 | 2024-02-19 | 2026-09-08 | |
| P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 126 | 2023-09-22 | 2026-04-13 |
| EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection. Antibiotic - standard duration, Antibiotic - fixed-extended-duration - Complicated Intra-abdominal Infection | Phase 3 | Active not recruiting | Lydia Flett | 1166 | 2022-10-10 | 2026-07-24 |
| Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection PF-06947386, Metronidazole - Complicated Intra-abdominal Infection | Phase 3 | Completed | Pfizer | 60 | 2021-10-01 | 2024-03-13 |
| A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. ATM-AVI, MTZ, MER - Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia | Phase 3 | Completed | Pfizer | 422 | 2018-04-05 | 2024-12-10 |
| MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Ceftolozane/Tazobactam, Metronidazole, Meropenem - Complicated Intra-Abdominal Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 94 | 2018-04-03 | 2023-05-06 |
| Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Imipenem+Cilastatin/Relebactam - Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 83 | 2017-10-04 | 2021-02-12 |
| Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g), metronidazole 500 mg - Intra-abdominal Infection, Complicated Intra-abdominal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 100 | 2016-04-08 | 2018-08-09 |
| Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole - Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection | Phase 3 | Completed | Pfizer | 345 | 2013-01-01 | 2017-09-29 |
| Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Ceftazidime-avibactam, metronidazole, Meropenem - Complicated Intra-abdominal Infection | Phase 3 | Completed | Pfizer | 486 | 2013-01-01 | 2017-09-06 |
| Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections CAZ-AVI, Metronidazole, Meropenem - Complicated Intra-Abdominal Infection | Phase 3 | Completed | Pfizer | 493 | 2012-03-01 | 2017-09-06 |
| Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections CXA-201 and metronidazole, Meropenem - Complicated Intra-abdominal Infection | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 494 | 2011-12-23 | 2018-11-16 |
| Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections TP-434, Ertapenem, Placebo - Complicated Intra-abdominal Infection | Phase 2 | Completed | Tetraphase Pharmaceuticals, Inc | 143 | 2011-01-01 | 2022-01-06 |
| Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin - Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection | Phase 3 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2011-01-01 | 2012-06-07 | |
| Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin - Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection | Phase 3 | Withdrawn | Pfizer | 2011-01-01 | 2013-02-22 | |
| Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo - Complicated Intra-abdominal Infection | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 122 | 2010-06-25 | 2018-10-25 |
| Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections no intervention - Complicated Intra-Abdominal Infection | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 203 | 2008-11-01 | 2012-08-10 | |
| A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) MK0826; ertapenem sodium, Comparator: ceftriaxone + metronidazole - Complicated Intra-abdominal Infection | Phase 4 | Completed | Merck Sharp & Dohme LLC | 134 | 2004-01-01 | 2017-02-20 |
Infections (3) · Intraabdominal Infections (2) · Pneumonia (2) · Healthcare-Associated Pneumonia (1) · Pneumonia, Ventilator-Associated (1)
Infections (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Cross Infection (2) · Disease Attributes (2) · Iatrogenic Disease (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Pneumonia (2) · Healthcare-Associated Pneumonia (1)
Metronidazole (11) · Meropenem (5) · Ertapenem (2) · Tazobactam (2) · Tigecycline (2) · avibactam, ceftazidime drug combination (2) · ceftolozane (2) · ceftolozane, tazobactam drug combination (1) · eravacycline (1) · imipenem, cilastatin and relebactam (1) · nacubactam (1)
Pfizer (7) · Merck Sharp & Dohme LLC (4) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Lydia Flett (1) · Meiji Seika Pharma Co., Ltd. (1) · Tetraphase Pharmaceuticals, Inc (1)
United States (7) · Argentina (5) · Bulgaria (5) · Croatia (5) · Israel (5) · Romania (5) · Russia (5) · South Korea (5) · Spain (5) · Czechia (4) · Latvia (4) · Mexico (4) · Turkey (Türkiye) (4) · Ukraine (4) · China (3)
Paul Newell, MBBS, MRCP (2) · Andrew Kirby, MD (1) · Ellie Hershberger, Pharm.D (1) · Ian Friedland, MD (1) · Patrick T Horn, MD, PhD (1) · Paul A Newell, MBBS, MRCP (1)
PMID 29912399, PMID 30061279, PMID 30221827, PMID 32602065, PMID 37700689, PMID 24342651, PMID 24982069, PMID 25670823, PMID 27139477, PMID 27872067, PMID 27999024, PMID 28348155, PMID 28363526, PMID 28446129, PMID 28464828, PMID 29686147, PMID 30528561, PMID 30910899, PMID 31890160, PMID 33191112, PMID 37000942, PMID 38252170, PMID 39389071, PMID 39710167, PMID 40530972, PMID 40913503, PMID 41269522
2016 (1), 2017 (1)